188 related articles for article (PubMed ID: 33382729)
21. Assessment of Drug Interaction Potential Between the Hepatitis C Virus Direct-Acting Antiviral Agents Elbasvir/Grazoprevir and the Nucleotide Analog Reverse-Transcriptase Inhibitor Tenofovir Disoproxil Fumarate.
Feng HP; Guo Z; Caro L; Talaty JE; Mangin E; Panebianco D; Fandozzi C; Zhu Y; Marshall W; Huang X; Hanley WD; Jumes P; Valesky R; Martinho M; Butterton JR; Iwamoto M; Yeh WW
Clin Pharmacol Drug Dev; 2019 Oct; 8(7):962-970. PubMed ID: 31173674
[TBL] [Abstract][Full Text] [Related]
22. Similar effectiveness of direct-acting antiviral against hepatitis C virus in patients with and without HIV infection.
Montes ML; Olveira A; Ahumada A; Aldámiz T; García-Samaniego J; Clemente A; Berenguer J; González-García J; Martín-Carbonero L;
AIDS; 2017 Jun; 31(9):1253-1260. PubMed ID: 28358742
[TBL] [Abstract][Full Text] [Related]
23. Managing hepatitis C therapy failures and chronic kidney disease.
Fabrizi F; Messa P
Expert Rev Clin Pharmacol; 2018 Nov; 11(11):1135-1142. PubMed ID: 30309263
[TBL] [Abstract][Full Text] [Related]
24. Imprint of unconventional T-cell response in acute hepatitis C persists despite successful early antiviral treatment.
Du Y; Khera T; Strunz B; Deterding K; Todt D; Woller N; Engelskircher SA; Hardtke S; Port K; Ponzetta A; Steinmann E; Cornberg M; Hengst J; Björkström NK; Wedemeyer H;
Eur J Immunol; 2022 Mar; 52(3):472-483. PubMed ID: 34843107
[TBL] [Abstract][Full Text] [Related]
25. Increased peripheral CD4
Langhans B; Nischalke HD; Krämer B; Hausen A; Dold L; van Heteren P; Hüneburg R; Nattermann J; Strassburg CP; Spengler U
J Hepatol; 2017 May; 66(5):888-896. PubMed ID: 28040549
[TBL] [Abstract][Full Text] [Related]
26. HIV-coinfected patients respond worse to direct-acting antiviral-based therapy against chronic hepatitis C in real life than HCV-monoinfected individuals: a prospective cohort study.
Neukam K; Morano-Amado LE; Rivero-Juárez A; Mancebo M; Granados R; Téllez F; Collado A; Ríos MJ; de Los Santos-Gil I; Reus-Bañuls S; Vera-Méndez F; Geijo-Martínez P; Montero-Alonso M; Suárez-Santamaría M; Pineda JA
HIV Clin Trials; 2017 May; 18(3):126-134. PubMed ID: 28599618
[TBL] [Abstract][Full Text] [Related]
27. Real-world use of elbasvir-grazoprevir in patients with chronic hepatitis C: retrospective analyses from the TRIO network.
Flamm SL; Bacon B; Curry MP; Milligan S; Nwankwo CU; Tsai N; Younossi Z; Afdhal N
Aliment Pharmacol Ther; 2018 Jun; 47(11):1511-1522. PubMed ID: 29665097
[TBL] [Abstract][Full Text] [Related]
28. Peripheral loss of CD8(+) CD161(++) TCRVα7·2(+) mucosal-associated invariant T cells in chronic hepatitis C virus-infected patients.
Barathan M; Mohamed R; Vadivelu J; Chang LY; Saeidi A; Yong YK; Ravishankar Ram M; Gopal K; Velu V; Larsson M; Shankar EM
Eur J Clin Invest; 2016 Feb; 46(2):170-80. PubMed ID: 26681320
[TBL] [Abstract][Full Text] [Related]
29. Hepatitis C virologic response in hepatitis B and C coinfected persons treated with directly acting antiviral agents: Results from ERCHIVES.
Butt AA; Yan P; Aslam S; Sherman KE; Siraj D; Safdar N; Hameed B
Int J Infect Dis; 2020 Mar; 92():184-188. PubMed ID: 31978574
[TBL] [Abstract][Full Text] [Related]
30. Grazoprevir plus elbasvir in HCV genotype-1 or -4 infected patients with stage 4/5 severe chronic kidney disease is safe and effective.
Alric L; Ollivier-Hourmand I; Bérard E; Hillaire S; Guillaume M; Vallet-Pichard A; Bernard-Chabert B; Loustaud-Ratti V; Bourlière M; de Ledinghen V; Fouchard-Hubert I; Canva V; Minello A; Nguyen-Khac E; Leroy V; Saadoun D; Trias D; Pol S; Kamar N
Kidney Int; 2018 Jul; 94(1):206-213. PubMed ID: 29735308
[TBL] [Abstract][Full Text] [Related]
31. Safety and efficacy of elbasvir/grazoprevir in Asian participants with hepatitis C virus genotypes 1 and 4 infection.
Wei L; Kumada H; Perumalswami PV; Tanwandee T; Cheng W; Heo J; Cheng PN; Hwang P; Mu SM; Zhao XM; Asante-Appiah E; Caro L; Hanna GJ; Robertson MN; Haber BA; Talwani R
J Gastroenterol Hepatol; 2019 Sep; 34(9):1597-1603. PubMed ID: 30779220
[TBL] [Abstract][Full Text] [Related]
32. Benefit of direct-acting antiviral therapy for hepatitis C virus (HCV) in monoinfected and HIV-HCV-coinfected patients with mixed cryoglobulinaemia.
Miailhes P; Hartig-Lavie K; Virlogeux V; Pradat P; Diakite M; Uhres AC; Zoulim F; Sarda MN
Clin Microbiol Infect; 2018 Nov; 24(11):1215.e1-1215.e4. PubMed ID: 29870852
[TBL] [Abstract][Full Text] [Related]
33. Safety and efficacy of elbasvir and grazoprevir for treatment of hepatitis C.
Carrion AF; Martin P
Expert Opin Drug Saf; 2016 Jun; 15(6):883-90. PubMed ID: 27091555
[TBL] [Abstract][Full Text] [Related]
34. Direct-acting antiviral therapy enhances total CD4+ and CD8+ T-cells responses, but does not alter T-cells activation among HCV mono-infected, and HCV/HIV-1 co-infected patients.
Najafi Fard S; Schietroma I; Corano Scheri G; Giustini N; Serafino S; Cavallari EN; Pinacchio C; De Girolamo G; Ceccarelli G; Scagnolari C; Vullo V; d'Ettorre G
Clin Res Hepatol Gastroenterol; 2018 Sep; 42(4):319-329. PubMed ID: 29279268
[TBL] [Abstract][Full Text] [Related]
35. Elbasvir/Grazoprevir: A Review in Chronic HCV Genotypes 1 and 4.
Al-Salama ZT; Deeks ED
Drugs; 2017 May; 77(8):911-921. PubMed ID: 28417245
[TBL] [Abstract][Full Text] [Related]
36. Integrated analysis of 8-week glecaprevir/pibrentasvir in Japanese and overseas patients without cirrhosis and with hepatitis C virus genotype 1 or 2 infection.
Naganuma A; Chayama K; Notsumata K; Gane E; Foster GR; Wyles D; Kwo P; Crown E; Bhagat A; Mensa FJ; Otani T; Larsen L; Burroughs M; Kumada H
J Gastroenterol; 2019 Aug; 54(8):752-761. PubMed ID: 30868245
[TBL] [Abstract][Full Text] [Related]
37. Clinical Pharmacokinetics and Drug-Drug Interactions of Elbasvir/Grazoprevir.
Kiang TKL
Eur J Drug Metab Pharmacokinet; 2018 Oct; 43(5):509-531. PubMed ID: 29557529
[TBL] [Abstract][Full Text] [Related]
38. High rates of hepatitis C virus (HCV) cure using direct-acting antivirals in HIV/HCV-coinfected patients: a real-world perspective.
Hawkins C; Grant J; Ammerman LR; Palella F; Mclaughlin M; Green R; Mcgregor D; Stosor V
J Antimicrob Chemother; 2016 Sep; 71(9):2642-5. PubMed ID: 27330060
[TBL] [Abstract][Full Text] [Related]
39. Pegylated interferon plus ribavirin in HIV-infected patients with recurrent hepatitis C after liver transplantation: a prospective cohort study.
Castells L; Rimola A; Manzardo C; Valdivieso A; Montero JL; Barcena R; Abradelo M; Xiol X; Aguilera V; Salcedo M; Rodriguez M; Bernal C; Suarez F; Antela A; Olivares S; Del Campo S; Laguno M; Fernandez JR; de la Rosa G; Agüero F; Perez I; González-García J; Esteban-Mur JI; Miro JM;
J Hepatol; 2015 Jan; 62(1):92-100. PubMed ID: 25127748
[TBL] [Abstract][Full Text] [Related]
40. Interferon-free therapy with direct acting antivirals for HCV/HIV-1 co-infected Japanese patients with inherited bleeding disorders.
Uemura H; Tsukada K; Mizushima D; Aoki T; Watanabe K; Kinai E; Teruya K; Gatanaga H; Kikuchi Y; Sugiyama M; Mizokami M; Oka S
PLoS One; 2017; 12(10):e0186255. PubMed ID: 29045448
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
